Biochem Biophys Res Commun (2018) 495(1):103440
13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service down from 16 in October 2025
GSM-directed therapy in peri/postmenopausal patients (or others with hypo-oestrogen states): NICE and UK resources support vaginal oestrogen as a local therapy for genitourinary symptoms of menopause, with patient counselling that systemic absorption is minimal and serious adverse effects are very rare
Some claim that it is good, while others question its safety, particularly for skin whitening
Variants in FTO , GLP1R , MC4R , and TCF7L2 map baseline appetite, energy-balance, and glucose biology
An active Eden Membership is required ($39 for the first month, auto-renews at $99/month thereafter)